Neurogene (NGNE) Expected to Announce Earnings on Monday

Neurogene (NASDAQ:NGNE) will likely be issuing its Q3 2025 results before the market opens on Monday, November 17th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, November 18, 2025 at 9:30 AM ET.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings data on Monday, August 11th. The company reported ($1.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.10. On average, analysts expect Neurogene to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Neurogene Trading Up 0.3%

NGNE stock opened at $26.75 on Monday. The company has a market capitalization of $381.78 million, a P/E ratio of -6.21 and a beta of 1.64. The business has a 50 day simple moving average of $24.43 and a 200-day simple moving average of $21.00. Neurogene has a twelve month low of $6.88 and a twelve month high of $74.49.

Institutional Trading of Neurogene

A hedge fund recently raised its stake in Neurogene stock. Bank of America Corp DE boosted its holdings in Neurogene Inc. (NASDAQ:NGNE) by 81.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 95,401 shares of the company’s stock after acquiring an additional 42,880 shares during the quarter. Bank of America Corp DE owned about 0.67% of Neurogene worth $1,426,000 as of its most recent filing with the SEC. Institutional investors own 52.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. HC Wainwright increased their price target on shares of Neurogene from $45.00 to $65.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Neurogene has a consensus rating of “Moderate Buy” and a consensus target price of $49.50.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.